Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.For the manufacture of Kevetrin active pharmaceutical ingredient
Subscribe to our email newsletter
Cellceutix has signed an agreement with Girindus America for the manufacture of Kevetrin active pharmaceutical ingredient. Terms of the agreement were not disclosed.
Kevetrin is being developed to treat certain cancers. The company has recently reported positive results in animal models of drug resistant lung cancers.
George Evans, CEO of Cellceutix, said: This is a big step toward our short-term goal of filing for an investigational new drug exemption (IND) with the FDA. We will use the material manufactured by Girindus to do the last animal studies needed for the filing of an IND, as well as for phase 1 human trials. We think Girindus will be an excellent partner for Cellceutix.